FDA approves an IND from Galecto Biotech for TD139 treatment of IPF patients. – Phase Ib/IIa Trial to Start in the UK

Copenhagen, March 1, 2015

Galecto Biotech AB today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for the company’s galectin-3 inhibitor, TD139, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Simultaneously, the company announced that a phase Ib/IIa trial in IPF patients is due to start shortly in several centers in the United Kingdom (UK).

Read more

Cookies Privacy Policy